24.2 C
New York
Thursday, June 11, 2026

Tag: biosimilar

newssourceFORcompanyinformationcontent1marketreleases

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026. 

APOTEX HEALTH CORP. UPSIZES ITS INITIAL PUBLIC OFFERING

/Not for distribution to U.S. news wire services or dissemination in the United States./TORONTO, June 8, 2026 /CNW/ - Apotex Health Corp. ("Apotex" or the...

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire...

Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire...

Lilly reports second-quarter 2025 financial results and raises guidance

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year...

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

How Women Can Tame Medication Costs for the Whole Family

MISSION, Kan., Aug. 4, 2025 /PRNewswire/ -- (Family Features) If you're the one tracking medications, scheduling appointments and making sure the whole household stays...

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa

KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a global partner of biopharmaceutical manufacturing, have announced a partnership to accelerate Africa’s biopharmaceutical industry and address the continent’s urgent, dual health burdens in infectious and non-communicable diseases.

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, ‘EYLUXVI® (ALT-L9)’

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea®Upon approval, EYLUXVI® will...

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

- A word from our sponsors -

spot_img
HomeTagsBiosimilar

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers